Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma

Inclusion criteria : I1. Male or female patients aged ≥ 18 years old at time of inform consent signature. I2. Patients with primary head and neck tumour up to, but not crossing the midline, previously untreated with histologically-confirmed squamous cell carcinoma of: * the oropharynx p16-, larynx or hypopharynx : T1/N2a-N2b, T2/N0-N2b, T3/N0-N2b (UICC 8th Ed.), or * the oropharynx p16+ : T1/N1 (multiple nodes), T2-T3/N0-N1 (UICC 8th Ed.). I3. Patients with lymph node staging assessed by an FDG-PET/CT with no contralateral nodal uptake. I4. Patients amenable to treatment with RT or concomitant chemo-radiotherapy as decided by the treating physician as a function of tumor stage, tumor location, performance of the patients. I5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1. I6. Adequate hematologic and end-organ function, defined by the following laboratory test results obtained within 7 days prior to randomisation : Hematological (without transfusion within 2 weeks) : * Neutrophils count \> 1.5 × 109 /L * Platelets count \> 75 × 109 /L * WBC≥ 3.0 × 109 /L Hepatic function : * Total Bilirubin \< 1.5 × ULN (except for Gilbert's syndrome which will allow bilirubin ≤ 3 ULN). * Alanine aminotransferase (ALT) ≤ 2.5 × ULN. * Aspartate aminotransferase (AST) ≤ 2.5 × ULN. * Albumin \>3.0g/dL Renal function : * Serum creatinine \< 1.5 ×ULN. I7. QTcF ≤450ms for men and 470ms for women, from 3 electrocardiograms on screening ECG, within 7 days prior ran…